血压
胰高血糖素样肽-1
肠促胰岛素
受体
葡萄糖稳态
兴奋剂
内分泌学
内科学
医学
激素
胰高血糖素样肽1受体
平衡
血糖性
胰高血糖素
糖尿病
2型糖尿病
胰岛素抵抗
作者
João Carlos Ribeiro-Silva,Caio A.M. Tavares,Adriana Castello Costa Girardi
标识
DOI:10.1016/j.coph.2023.102355
摘要
The incretin hormone glucagon-like peptide 1 (GLP-1) is a key component of the signaling mechanisms promoting glucose homeostasis. Clinical and experimental studies demonstrated that GLP-1 receptor agonists, including GLP-1 itself, have favorable effects on blood pressure and reduce the risk of major cardiovascular events, independently of their effect on glycemic control. GLP-1 receptors are present in the hypothalamus and brainstem, the carotid body, the vasculature, and the kidneys. These organs are involved in blood pressure regulation, have their function altered in hypertension, and are positively benefited by the treatment with GLP-1 receptor agonists. Here, we discuss the potential mechanisms whereby activation of GLP-1R signaling exerts blood pressure-lowering effects beyond glycemic control.
科研通智能强力驱动
Strongly Powered by AbleSci AI